Cellply develops analytical tools for cell therapy and regenerative medicine, with its flagship VivaCyte platform at the center of its commercial strategy. VivaCyte combines patented microfluidic technology, AI-powered automated image analysis, comprehensive automation, and dedicated software to enable characterization of immunotherapies and cell-based therapies at single-cell resolution. The company is prioritizing international expansion of VivaCyte and the development of automated functional testing solutions to improve cell potency assessment and streamline batch release for ATMPs. Cellply framed these quality-control solutions as critical to enabling scalability, sustainability, and broader patient access to complex and personalized medicines. The company has strengthened its board with the addition of Miro Venturi as it scales commercially. Cellply aims to become a global leader in analytical tools for research and quality control in the cell therapy and regenerative medicine sectors.

Total raised

$15M

Funding rounds

3

Latest round

Equity

Latest activity

May 2026